BGT-002

BGT-002 is a novel small molecule inhibitor of ATP-citrate lyase (ACLY), developed as an oral therapy for hypercholesterolemia and non-alcoholic steatohepatitis (NASH). By inhibiting ACLY, BGT-002 reduces de novo lipid synthesis in the liver, promotes fatty acid oxidation, lowers LDL cholesterol levels, and improves hepatic inflammation and fibrosis. Clinical studies have shown that BGT-002 is well-tolerated and effective at lowering LDL-C in patients with hypercholesterolemia, with efficacy comparable to or potentially greater than existing ACLY inhibitors such as Nexletol. In preclinical NASH models and early clinical trials for NAFLD/NASH, BGT-002 demonstrated significant improvements in liver fat content, lipid profiles, inflammatory markers (such as hs-CRP), and reversal of hepatic fibrosis[1][2][3][4][5].